IAV (ssRNA) |
NLRP3-dependent CASP1 activation; IL-1β and IL-18 release |
CASP8/3/7 activation |
RIPK1/RIPK3/MLKL signaling activation |
ZBP1 PANoptosome formation and activation |
(10, 77) |
Murine hepatitis virus (ssRNA) |
NLRP3 inflammasome activation; CASP1 activation and GSDMD cleavage |
CASP8/3/7 activation |
phosphorylated MLKL |
ZBP1 PANoptosome formation and activation |
(89, 90) |
SARS-CoV-2 (ssRNA) |
CASP1 activation and GSDMD cleavage; IL-1β and IL-18 release |
CASP8/9/3/7 activation |
RIPK1/RIPK3/MLKL signaling activation |
ZBP1 PANoptosome formation and activation |
(89, 91, 92) |
Yersinia pestis
|
CASP1 activation and GSDMD cleavage |
CASP8/3/7 activation |
RIPK1/RIPK3/MLKL signaling activation |
RIPK1 PANoptosome formation and activation |
(12) |
Staphylococcus aureus
|
NLRP3 inflammasome activation; CASP1 activation and GSDMD cleavage; IL-1β and IL-18 release |
CASP3 activation |
RIPK1/RIPK3/MLKL signaling activation |
NLRP3 inflammasome (PANoptosome) formation and activation |
(93–95) |
Listeria monocytogenes
|
NLRP3 inflammasome activation; CASP1 activation |
CASP3 activation and Bcl-2 inhibition |
RIPK1/RIPK3/MLKL signaling activation |
NLRP3 inflammasome (PANoptosome) formation and activation |
(96–98) |
C. albicans and A. fumigatus
|
NLRP3 inflammasome activation; CASP1 activation and GSDMD cleavage |
CASP8/3/7 activation |
RIPK3/MLKL signaling activation |
ZBP1 PANoptosome formation and activation |
(11) |